RxDoctor Payments Data

Norman Berkman, MD

Internal Medicine · Houston, TXNPI 1821187865

Payments from drug & device makers

$9,317in general payments, 2019–2025

Across 497 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Amgen$971
  • AbbVie$899
  • Novo Nordisk$774
  • Supernus Pharmaceuticals, Inc.$510
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$9,317100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,317 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$48,327
Medicare patients
141
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide55$54,689
OzempicSemaglutide46$42,657
EliquisApixaban30$32,060
XareltoRivaroxaban15$9,956
FarxigaDapagliflozin Propanediol17$9,683
MyrbetriqMirabegron13$8,743
PremarinEstrogens, Conjugated13$4,041
SynthroidLevothyroxine Sodium27$2,236
Levothyroxine Sodium166$2,167
Icosapent Ethyl12$2,086
Atorvastatin Calcium146$1,300
Rosuvastatin Calcium46$1,102
Ezetimibe31$971
Escitalopram Oxalate43$968
Losartan Potassium77$921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,007$54,68955 claims
Novo NordiskOzempic$774$42,65746 claims
PfizerEliquis, Premarin$229$36,10143 claims
AstraZenecaFarxiga$1,061$9,68317 claims
Astellas Pharma US IncMyrbetriq$477$8,74313 claims
AbbVieSynthroid$899$2,23627 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$35$2,167166 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →